Nachrichten zur ABBVIE Aktie

…

Market volatility persists on data center regulation concerns and rate expectations, as MarketBeat writers analyze earnings from AbbVie, Apple, Amazon,…

As tech stocks retreat, AbbVie (ABBV) and Eli Lilly (LLY) are hitting fresh 52-week highs, offering investors defensive healthcare exposure…

Skyrizi and Rinvoq drive double-digit growth as management raises full-year guidance.…

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q326 results.…

Despite its high price relative to earnings, AbbVie remains an attractive stock.…

Bristol Myers edges out AbbVie with a cheaper valuation and higher dividend yield, but pipeline execution, legacy drug declines and…

They definitely matter... up to a point.…

The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.…

As Formula 1 races into Austin, Texas for the United States Grand Prix at Circuit of the Americas, McLaren and…

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin…

Key TakeawaysAbbVie lowered its 2026 adjusted EPS guidance to $13. 76 to $13.…

Pfizer Inc. (NYSE:PFE) trades at a considerable discount to AbbVie Inc. (NYSE:ABBV), despite both companies reporting growth in important parts…

Sanofis upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine…

Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…

Youll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and…

ABBVs Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.…

ABBVs epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III studys PFS…

AbbVies FDA approval of Juvmo expands its Parkinsons portfolio, with a commercial launch targeted for October 2026.…

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly…

AbbVies stock climbs 25.4% in six months as Skyrizi, Rinvoq and neuroscience drugs fuel growth, but Humira erosion and competitive…

ABBV wins FDA approval for Juvmo, expanding its Parkinsons portfolio with a once-daily oral treatment and potential $5B-plus PD opportunity.…

AbbVie ist ein führender Biopharma-Konzern und ersetzt den Humira-Rückgang zunehmend mit neuen Wachstumstreibern aus Immunologie, Neurologie und Onkologie. Skyrizi…

GOOGL, MA and ABBV headline todays research, with AI-led growth, electronic payments and strong drug portfolios shaping their outlooks.…

AbbVie bets on pipeline diversification amid patent cliffs, while J&Js higher profitability masks litigation risks, a choice between growth ambition…

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and…

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran…

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly…

AbbVie and Pfizer are reshaping their growth strategies as new drugs, acquisitions, pipelines and patent challenges shape their outlooks.…

These companies are committed to rewarding shareholders.…

AbbVie’s Rinvoq wins EU approval for pediatric arthritis…

AbbVies market-beating days dont seem to be over yet.…

Citadel, Ken Griffins hedge fund, materially increased its stake in AbbVie; heres why you may want to follow that lead.…

The latest trading day saw AbbVie (ABBV) settling at $261.7, representing a +1.78% change from its previous close.…

ABBVs atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.…

AbbVies diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.…

ABBVs Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.…

…

BERLIN (dpa-AFX) - Immer mehr Menschen lassen minimalinvasive Eingriffe beim Schönheitschirurgen durchführen. Zu minimalinvasiven Eingriffen gehören…